287 related articles for article (PubMed ID: 9408151)
1. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action.
Imam H; Gobl A; Eriksson B; Oberg K
Anticancer Res; 1997; 17(6D):4659-65. PubMed ID: 9494585
[TBL] [Abstract][Full Text] [Related]
3. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.
Eriksson B; Renstrup J; Imam H; Oberg K
Ann Oncol; 1997 Oct; 8(10):1041-4. PubMed ID: 9402179
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
5. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
[TBL] [Abstract][Full Text] [Related]
6. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
7. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
8. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
[TBL] [Abstract][Full Text] [Related]
9. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
10. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of digestive neuroendocrine tumours].
Panzuto F; Nasoni S; Delle Fave G
Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
Igaz P
Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
[TBL] [Abstract][Full Text] [Related]
13. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
15. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
Ludlam WH; Anthony L
Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
[TBL] [Abstract][Full Text] [Related]
16. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
18. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.
Fjällskog ML; Sundin A; Westlin JE; Oberg K; Janson ET; Eriksson B
Med Oncol; 2002; 19(1):35-42. PubMed ID: 12025889
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
[TBL] [Abstract][Full Text] [Related]
20. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
